|

ANCILLARY EVENTS
|
|
26,27,28 September |
|
|
|
| |
|


Agenda (.Pdf)





|
 |
PROGRAM |
| |
|
| Select the type of Session :
|
|
Biotech researchers and entrepreneurs will all agree that one key success factor in this field is keeping an open mind and nurturing curiosity – sharing experiences, providing feedback, taking up new challenges, contemplating novel organizational structures, developing collaborative working methods and trying solutions that have worked in other fields. EuroBiO's seminar program will provide delegates with the latest information, cutting-edge insight and practical advice from nearly 200 top-level speakers in 4 tracks: the biotech economy and business development, red biotech, green & white biotech and technology transfer.
|
Wednesday September 26 th, 2007
 | BIOTECH ECONOMY AND BUSINESS DEVELOPMENT |
| 09:30 - 11:00 | | A look at 2007 early-stage investments : top stories and trends.
|
| After a growth year in 2006, will the deal flow for early-stage investments continue to increase in 2007? Are VC investors really moving downstream in favor of more pragmatic expansion, M&A and development deals? Does the "funding gap" still exist? Early-stage investment is traditionally an area where institutional policies and public funding can have a significant, immediate impact – is this indeed happening? In this morning's session, a panel of reference venture capitalists will review the deals that have hit the headlines in 2007 thus far and look at emerging trends in early-stage investment.
|
| Chairman | | | France | Sofinnova Partners | | Speakers | | | United Kingdom | Critical I | | | Sweden | Biotechnology Policy Desk - European Commission | | | United Kingdom | Novexel |
| 11:00 - 11:30 | | Coffee Break
|
| 11:30 - 12:30 | | PLENARY SESSION
|
| 14:00 - 16:00 | | Risk Sharing Finance Facility: a new European financial tool
|
| The European Commission and the European Investment Bank have created a new financial tool to help European Research: Risk Sharing Finance Facility (RSFF). This seminar aims to present this mechanism and how this instrument can be implemented to boost your financial resources inside your R&D project. This session will be animated by CDC, a French financial public institution involved in the coordination of FP Research Consortiums and member of AFINAJ, the French NCP for administrative, financial and legal issues for FP7.
|
| Chairman | | | France | Caisse des dépôts | | Speakers | | | Luxembourg | European Investment Bank | | | Luxembourg | European Investment Bank | | | Belgium | European Commission |
| 16:30 - 18:30 | | Fiscal Policy of Innovation: the French YIC status and its European equivalents.
|
| Since its launch in 2004, France's "Young Innovative Company" (YIC) fiscal status has been a runaway success, with over 1600 of the country's privately-owned hi-tech companies benefiting from a range of tax exemptions and reduced salary overheads for research-focused staff. The resulting savings have been reinvesting by purchasing R&D equipment and initiating collaborative projects, with a corresponding knock-on effect on innovation and business competitiveness. Other European countries have adopted (or are due to adopt) this type of fiscal policy on innovation. This seminar features Europe-wide feedback from entrepreneurs and guidance from institutional experts.
|
| Chairman | | | Belgium | EuropaBio | | Speakers | | | Sweden | Sweden Bio | | | France | Innate Pharma |
 | RED BIOTECH |
| 09:30 - 11:00 | | Nanobiotech applications in drug delivery - Linking Biotech and Medtech: the Nanomics revolution.
|
| There is no doubt that biotechnology, medical technology and nanotechnology are now well-established economic sectors in their own right, with each generating a steady stream of innovative products and services. But is the much-heralded nanobiotechnology revolution really here? With nanopumps, nano-injectors, smart pills & patches and related drug/device hybrids, drug delivery looks to be one application where biomolecular and semiconductor-based technologies are truly merging to address unmet medical needs.
|
| Chairman | | | Israel | Marian Gertner Institute for Medical Nanosystems, Tel-Aviv University | | Speakers | | | France | Pierre Fabre Medicament | | | Belgium | UCB | | | Israel | Marian Gertner Institute for Medical Nanosystems, Tel-Aviv University | | | France | AFSSAPS |
| 11:00 - 11:30 | | Coffee Break
|
| 11:30 - 12:30 | | PLENARY SESSION
|
| 14:00 - 16:00 | | Development of Applied and Basic Research in the field of Inflammatory Bowel Diseases.
|
| Advances in basic research have now prompted the realization that what used to be described over-casually as "the runs" can sometimes be a sign of serious, chronic conditions like ulcerative colitis and Crohn's disease. Given that environmental, dietary and genetic factors may all play a role, performing rigorous and informative applied research is a true challenge. This seminar will provide attendees with a comprehensive overview of the latest progress in this field, from basic bioscience to pharmaceutical product development & testing.
|
| Chairman | | | France | INSERM | | Speakers | | Salvatore Bellinvia | Italy | Giuliani S.p.A. | | Claude Gaultier | France | INSERM | | | Switzerland | FERRING Pharmaceuticals | | | Italy | Cosmo Pharmaceuticals S.p.A. | | | France | French Ministry for Research |
| 16:30 - 18:30 | | Use of Biomarkers for the optimization of clinical trials.
|
| Not so long ago, biomarkers used to be the sole preserve of biochemists and technologists more interested in developing ultra-sensitive analytical techniques than meeting clinical needs. However, as clinicians, CROs and drug companies become increasing aware of the power of being able to monitor disease status/susceptibility and the body's response to treatment, biomarkers are now being used as surrogate clinical trial endpoints in all the major fields of medicine, including transplantation, cancer and cardiovascular, neurodegenerative & immune/inflammatory diseases.
|
| Chairman | | | Canada | Ontario Cancer Biomarker Network | | Speakers | | | France | Biofortis | | | Canada | Ontario Cancer Biomarker Network | | Bastiaan van der Baan | Netherlands | Agendia |
 | WHITE AND GREEN BIOTECH |
| 09:30 - 11:00 | | Bioremediation & phytoremediation of soils/ water
|
| Bioremediation is now acknowledged as a flexible and cost-effective tool for cleaning up wastewater, groundwater and soil. But do we have the right molecular analysis and process tools to monitor and control the process in situ? How does bioaugmentation compare with biostimulation? Can the bioremediation of waste be linked to bioenergy generation? What will be the role of GMOs in phytoremediation? This seminar features scientific insight and practical advice from academic experts and industrial innovators from around the world.
|
| Chairman | | | United States | Georgia Institute of Technology | | Speakers | | | Canada | GeoSyntec | | | Canada | University of Toronto | | | Korea | Dailbiotech corp |
| 11:00 - 11:30 | | Coffee Break
|
| 11:30 - 12:30 | | PLENARY SESSION
|
| 14:00 - 16:00 | | Biocatalysis (enzymes & micro-organisms for organic synthesis in the chemical industry).
|
| The surprisingly mature field of biocatalysis is offering cost-effective, competitive solutions – there is an economic "pull" as well as a regulatory "push", with multi-step organic syntheses often being replaced by a single, enantioselective, biocatalyzed reaction using native or engineered enzymes or whole cells. However, the chemical industry requires the same process development speed and purity levels as in its traditional organic approach - so can biochemical engineers meet this challenge and collaborate intelligently with industrial chemists?
|
| Chairman | | | Netherlands | DSM | | Speakers | | | Austria | Research Centre Applied Biocatalysis | | | France | Proteus | | | Germany | c-LEcta GmbH |
| 16:00 - 16:30 | | Coffee Break
|
| 16:30 - 18:30 | | Nutrigenomics : Recent Scientific Advances & Applications
|
| As a fine example of systems biology (where gene x environment interactions are crucial), nutrigenomics has been given mainstream legitimacy by the flood of lactose-free dairy products now marketed for hypolactasic individuals. Nutrigenomics is injecting hard science into anecdotal dietary & fitness practices, as gene polymorphism tests and micronutrient assays now go hand-in-hand with lifestyle counseling. Our panel of specialists will present the latest scientific advances in nutrigenomics and its real-life applications.
|
| Chairman | | | Netherlands | TNO Quality of Life-NuGo, the European Nutrigenomics Association | | Speakers | | | Netherlands | Wageningen University | | | Switzerland | DSM Nutritional Products Ltd | | | United Kingdom | Unilever Corporate | | | Canada | University of Guelph |
 | TECHNOLOGY TRANSFER |
| 09:30 - 11:00 | | How to access EU grants. The 7th Framework programme and EUREKA's Eurostars initiative: opportunities for European entrepreneurs and experiences.
|
| Broadening participation in EU research and technological development (RTD) programs is a priority on both the regional and national levels (the ERA-NET scheme) or as part of transnational collaborative projects (FP7). Despite the availability of relatively large amounts of funding and sometimes high grant approval rates, Europe's entrepreneurs are still dissuaded by enduring clichés of bureaucracy. This session features feedback from entrepreneurs, advice from consultants and dialogue with Commission officials.
|
| Chairman | | | Ireland | Horizontal Aspects & Coordination Unit - Health Directorate DG Research European Commission | | Speakers | | | Netherlands | Eurostars / EUREKA | | | Ireland | Horizontal Aspects & Coordination Unit - Health Directorate DG Research European Commission | | | Spain | Oryzon Genomics | | | Germany | European Research and Project Office GmbH (EURICE) |
| 11:00 - 11:30 | | Coffee Break
|
| 11:30 - 12:30 | | PLENARY SESSION
|
| 14:00 - 16:00 | | BioIncubators’ Mentoring & advising teams: required skills and successful organisational models.
|
| With bioincubators sprouting up everywhere, have issues like staffing policy, continuing professional development and organizational structures been given enough thought? What skills do the mentoring & advising teams need to have in order to provide optimal project support to budding entrepreneurs? What backgrounds and profiles are most effective? And are bioincubators themselves sufficiently innovative in terms of their organizational structures, business practices and operating procedures? Our expert panel from across Europe will provide answers and highlight solutions.
|
| Chairman | | | United Kingdom | Babraham Biosciences Technologies | | Speakers | | | Israel | RAD BioMed Incubator | | | United Kingdom | BioCity Nottingham | | | Spain | Barcelona Science Park | | | Belgium | WBC Incubator |
| 16:00 - 16:30 | | Coffee Break
|
| 16:30 - 18:30 | | Technology Transfer: from academia to big companies: financial and technical requirements for a successful out-licensing process
|
| Despite the kudos (and risk) of spinning out hi-tech start-ups, out-licensing to large companies is still the predominant tech transfer activity in academia. Multinationals generally have well-structured, easy-access academic liaison offices, with "standard" agreements & licensing procedures and linked incentives for collaborative research opportunities (industrial studentships, postdocs) that faculty researchers find very attractive. This seminar will focus on the financial, technical, legal and IP-related aspects of successful out-licensing.
|
| Chairman | | | United Kingdom | University of Ulster | | Speakers | | | Belgium | Zentech s.a. | | | United Kingdom | PharmaLinks | | | Netherlands | NIZO Food Research | | | Belgium | Gesval |
Thursday September 27 th, 2007
 | BIOTECH ECONOMY AND BUSINESS DEVELOPMENT |
| 09:00 - 10:30 | | Follow-on Financing of European Biotech after the IPO
|
| Yes, there is life after an IPO! Of course, stock market flotation is a key milestone and the path there is a long one - so company managers can be tempted to rest on their laurels once the ticker tape starts streaming. However, publicly quoted firms are then firmly in the regulatory and media spotlight and must continue to deliver (and be seen to deliver) shareholder value. This seminar explores how to maintain post-IPO momentum and reviews the opportunities for growth via secondary public offerings and other follow-on financial instruments.
|
| Chairman | | | United Kingdom | NicOx | | Speakers | | | Belgium | Strategus | | | United Kingdom | Merrill Lynch - European Healthcare Investment Banking | | Marc le Bozec | France | Cellectis |
| 10:30 - 11:00 | | Coffee Break
|
| 11:00 - 12:30 | | Adding value to the development of Biotech - derived medicinal products from the European regulatory perspectives.
|
| Regulatory regimes for biotech-derived medicinal products have to strike a sometimes delicate balance between protecting the public from potentially hazardous products on one hand and giving patients rapid access to life-saving and/or QoL-boosting medications on the other. By taking these issues into account during the development process, biopharmaceutical companies can add significant value to their product portfolios and facilitate the marketing authorization process. Our expert speakers will tell you how!
|
| Chairman | | | United Kingdom | Regulatory Affairs - ERA Consulting | | Speakers | | | United Kingdom | ImmunoBiology Ltd | | | Austria | Austrianova Biotechnology GmbH | | | Germany | NDA Regulatory Science Ltd. |
| 12:30 - 14:00 | | Lunch Break
|
| 14:00 - 16:00 | | What types of opportunities are pharmaceutical companies looking to invest in ? Biotech / Pharma: Case studies.
|
| These days, big pharma is spoilt for choice in terms of potential alliance and investment opportunities worldwide. So what are the key success factors for clinching a deal with a major corporate partner? Are geographical factors relevant? How far down the value chain does a project have to be? This session gives you the chance to hear it "straight from the horse's mouth", with testimonies and case studies presented by representatives from global pharma players.
|
| Chairman | | | France | Gold Islands | | Speakers | | | France | Bionest Partners | | | France | Gold Islands | | | United Kingdom | Pfizer | | | France | LibraGen |
| 16:00 - 16:30 | | Coffee Break
|
| 16:30 - 18:30 | | Biotech to Biotech Strategic and Economic Alliances in 2007 : lessons & perspectives
|
| With the emergence of "big biotech" and the sometimes fluctuating windows of opportunity for IPOs, the last couple of years have testified to the realization that biotech-to-pharma deals are not the only opportunities for external growth and partnering. A professionally managed biotech-to-biotech alliance with a solid strategic and economic basis can deliver early revenue streams and long-term shareholder value. Senior managers from European and North American biotech firms share their experience.
|
| Chairman | | | United Kingdom | Critical I | | Speakers | | | United States | GTC Biotherapeutics | | | France | Genfit | | | France | LFB BIOTECHNOLOGIES | | | France | LFB BIOTECHNOLOGIES |
 | RED BIOTECH |
| 09:00 - 10:30 | | Regenerative medicine - Main cell therapy & organ regeneration breakthroughs in 2007.
|
| With stem cell technologies regularly grabbing the headlines, we should bear in mind that regenerative medicine covers a broad range of technologies (from organ-, cell- and tissue-based allotransplantation and autologous implantation to smart 2-D and 3-D artificial polymeric scaffolds) and is being applied in almost all organ systems and disease areas. Academic researchers, life science companies, patient groups and regulators are steadily resolving the technical, biological and ethical issues, with a view to routine use of these remarkably powerful procedures. This session will review the year's main breakthroughs in this exciting field of medicine.
|
| Chairman | | | United Kingdom | Stem Cell Sciences | | Speakers | | | United Kingdom | Stem Cell Sciences | | | Belgium | Bone Therapeutics | | Mark Furth | United States | Wake Forest University School of Medicine | | | Finland | REGEA Institute for Regenerative Medicine |
| 10:30 - 11:00 | | Coffee Break
|
| 11:00 - 12:30 | | Highlights on early stage drug candidates in the field of Alzheimer’s disease.
|
| In developed countries, Alzheimer's disease affects approximately 5 per cent of the over-65s, and this figure is set to rise. A number of acetylcholine esterase inhibitors are currently on the market but few experts would contest the need for more effective medications. Hence, biopharmaceutical companies are not only seeking better cholinergic drugs but are also turning to new mechanisms of action (such as NMDA receptor antagonists) and compounds which improve blood-vessel function (such as some diuretics and beta-blockers). This authoritative session will present a number of exciting discovery & development projects.
|
| Chairman | | | France | INSERM CNRS | | Speakers | | | France | INSERM CNRS | | | Germany | Evotec Neurosciences | | | Switzerland | Merck Serono International | | | Austria | AFFIRIS GmbH |
| 12:30 - 14:00 | | Lunch Break
|
| 14:00 - 16:00 | | Cardiometabolic diseases: Innovation pipeline review.
|
| The last decade has witnessed an explosion in the prevalence of cardiovascular disease and metabolic syndromes in developed countries. Diabetes, hypertension, stroke, obesity, overweight... recent scientific advances have prompted a growing awareness that these conditions are complex cardiometabolic syndromes with multiple (but often interrelated) risk factors. This session provides insight into today's therapeutic pipelines, with a special focus on the multimodal drug approach – the optimized use of a single compound to treat several conditions, with inherent advantages in terms of better compliance and fewer drug-drug interactions.
|
| Chairman | | | Belgium | Genfit / University Lille II | | Speakers | | | Canada | Genfit SA | | | France | Solvay/Fournier | | | Germany | Center for Cardiovascular Research, Charite | | | United States | Takeda |
| 16:00 - 16:30 | | Coffee Break
|
| 16:30 - 18:30 | | Integrative Discovery Informatics
|
| Critics argue that bioinformatics has failed to deliver the pipeline productivity that was much heralded in the late 1990s and early 2000s. However, machine-centric approaches based solely on computing power and database volume have given way to smarter, more integrated platforms where bioinformatics specialists are true members of the discovery team, with a clear understanding of the scientific and corporate issues in today's biopharmaceutical industry. This session provides cutting-edge comment from global leaders.
|
| Chairman | | | France | INRIA / GENOSTAR | | Speakers | | Hans Geiselmann | Germany | Université Joseph Fourrier | | | France | Microsoft Corporation Healthcare Life Science | | David Monteau | France | INRIA | | | United States | GenomeQuest |
 | WHITE AND GREEN BIOTECH |
| 09:00 - 10:30 | | Micro-organisms & Functional food: how can pre/probiotics improve quality of life ?
|
| Prebiotics and probiotics are now mainstream food products – at least for "early adopters". However, simply saying "eat this, it's good for you" may not be enough to make most consumers change their dietary habits! Delivery of visible, direct, individual benefit - quality of life, in short – has become a major issue. Pre/probiotics are now being tested clinically using validated, disease-specific QoL scales in conditions as varied as chronic rhinosinusitis, Crohn’s disease and hepatic cirrhosis. Come and listen to a series of insightful presentations by start-ups, multinationals and academics.
|
| Speakers | | | France | INSERM | | | Germany | Organobalance GmbH | | | Switzerland | Nutrition & Health - Nestlé Research Center | | | Germany | Federal Research Centre for Nutrition and Food |
| 10:30 - 11:00 | | Coffee Break
|
| 11:00 - 12:30 | | Bioprocesses: design and development of large scale / complex processes.
|
| At a time when around half of all newly marketed drugs are biomanufactured, bioprocess design, scale-up and optimization are becoming "mission-critical" in the industry. But as volumes go up, micro-environments can cause recombinant protein yields to fall or trigger the expression of previously silent genes... Which technical skills, technology platforms and collaborative methods are needed for success in capital-hungry, large-scale GCP/GMP bioprocesses? This session's expert speakers will provide a focused but widely applicable snapshot of ongoing developments in this exciting field.
|
| Chairman | | | France | Amgen | | Speakers | | | Sweden | Novozymes Biopharma AB | | | United Kingdom | Eden Biodesign | | | Netherlands | TNO Quality of Life |
| 12:30 - 14:00 | | Lunch Break
|
| 14:00 - 16:00 | | Food, Agriculture and Animal: Innovative products from genomic research - Plant- & Animal-based recombinant products.
|
| Despite the persistence of regulatory & ethical issues, plant- and animal-based recombinant products are capable of adding value to the agricultural, medical and feed & food sectors. High-throughput studies of pest resistance biomarkers herald higher but more sustainable yields for economically important crops, whilst genotyping techniques can profile population dynamics in plant and animal species and help conserve biodiversity. In the medical field, transgenesis technology enables production of high-added-value proteins in the milk of farm animals. Experts from around the world will provide insight and commentary on the latest innovations and products.
|
| Chairman | | Marc Zabeau | Belgium | Flanders Institute for Biotechnology / European Plant Science Organisation | | Speakers | | | France | LFB BIOTECHNOLOGIES | | | United States | GTC Biotherapeutics | | | Canada | Trent University / Genopod | | | Netherlands | Keygene |
| 16:00 - 16:30 | | Coffee Break
|
 | TECHNOLOGY TRANSFER |
| 09:00 - 10:30 | | When Europe rediscovers the virtues of public / private research consortia - Competitiveness clusters: the French collaborative research and its European equivalent models.
|
| At last, Europe's academics, corporate players and legislators have realized that public-private sector research collaboration and consortia can be effective and mutually beneficial – academics are not solely focused on publication and companies are not just there to rip off academics...! Since 2005, France has been pioneering its "competitiveness clusters", with strong regional management and significant amounts of state funding for accredited public-private consortia. How do these clusters compare with other models across Europe? Come and listen to experts from organizations which are developing new approaches to innovation and knowledge generation.
|
| Chairman | | | France | Lyon Biopole | | Speakers | | | Netherlands | Leiden BioScience Park | | | Italy | Bioindustry Park del Cavanese | | | Belgium | BIOWin |
| 09:00 - 10:30 | | Biobanks: current bioethics and organizational issues
|
| Biobanks (also known as biological resource centers) are now essential tools in basic & applied bioscience, clinical investigation and, increasingly, medical care itself. Cutting-edge automated sample processing, identification, storage, retrieval and analysis technologies and early adoption of standard operating procedures and good laboratory practice mean that most true biobanks are extremely professional organizations. But as technical and scientific horizons are being pushed back, have the organizational and ethical issues moved on too?
|
| Chairman | | | France | INSERM Transfert | | Speakers | | | France | Inserm / CNRS | | | United Kingdom | The Ethox Centre, University of Oxford | | | Austria | Medical University of Graz |
| 10:30 - 11:00 | | Coffee Break
|
| 11:00 - 12:30 | | Models of organization of translational research networks in Europe
|
| Translation research (broadly defined as translating ideas, knowledge and expertise acquired though basic scientific enquiry into improved disease prevention, diagnosis and treatment) is one of today's hottest topics, with its own learned journals, funding schemes and collaborative networks. However, going "from the bench to the bedside" involves a variety of different organizational models worldwide, with varying degrees of commitment from the public and private sectors. In fact, can translational research become a European theme "par excellence"?
|
| Chairman | | Jacques Demotes | France | ECRIN project coordinator - INSERM | | Speakers | | | Germany | Helmholtz Centre for Infection Research (HZI) | | Jacques Demotes | France | ECRIN project coordinator - INSERM | | | France | Lyon Biopole |
| 12:30 - 14:00 | | Lunch Break
|
| 14:00 - 16:00 | | Innovation in Biotechnology : Comparison of the Patenting process in Europe, Japan and the USA.
|
| Despite some recent harmonization measures (such as the publication of US patent applications), life science IP managers are today still having to cope with territory-specific patent filing, examination, grant & renewal procedures. Approaches to searching for information on patents, licensing and tech transfer activities also depend on the jurisdiction in question. In this session, leading patent experts will focus on key particularities of the USA and Japanese patent systems and will provide an overview of the current status of biotechnological inventions in France.
|
| Chairman | | | France | Cabinet Regimbeau | | Speakers | | | Belgium | Private investment and technology platforms - European Commission | | | Poland | Jagiellonian University - IPR-Helpdesk | | | United States | Lerner, David, Littenberg, Krumholz & Mentlik, LLP | | | France | European Patent Office | | | Japan | Ota & Associates, Patents & trademarks | | | France | Institut National de la Propriété Industrielle |
| 16:00 - 16:30 | | Coffee Break
|
| 16:30 - 18:30 | | Managing Successful Public - Private Research Collaboration : Key issues to succeed in a mutually successful relationship.
|
| As public-private research collaborations increasingly open up new R&D horizons and leverage the potential of individual institutions and companies, project management skills are becoming more important than ever. With today's detailed, formatted consortium agreements and extensive legal input, is there still a role for personal trust and informal working relationships? How can IP protection and academic publication be pursued successfully in parallel? How will cluster-based funding and national/regional networks (such as ERA-NET) influence "good collaboration practice"? Industry experts and academic project leaders & coordinators will provide you with feedback and advice on achieving a "win-win" partnership.
|
| Chairman | | | France | Sanofi Aventis | | Speakers | | | Belgium | ULB Interface | | Philippe Froguel | France | Imperial College London / CNRS Lille | | | Belgium | GSK Biologicals | | | France | OSEO | | | Belgium | Key Marker project |
Friday September 28 th, 2007
 | BIOTECH ECONOMY AND BUSINESS DEVELOPMENT |
| 09:00 - 10:30 | | How to succeed in the IPO process? Company check-up before an IPO: ready to float
|
| Stock market flotation is a key tool for raising the capital that your corporate development plan requires. But is your company ready to set sail on the sea of public equity finance? Is there a pre-IPO check-list? Do you have to plan that far ahead? At the same time, how can you react to windows of opportunity that sometimes open and close so rapidly? This seminar features testimonies from senior managers of companies that have floated recently on exchanges across Europe, plus feedback from the exchanges themselves.
|
| Chairman | | Gilles Avenard | France | BioAlliance Pharma | | Speakers | | | France | NicOx | | | Switzerland | SWX Swiss Exchange | | | Sweden | HealthCap | | | Germany | Paion |
| 10:30 - 11:00 | | Coffee Break
|
| 11:00 - 13:00 | | Questioning the efficiency of Drugs regulations: A critical look.
|
| Worldwide, drug regulatory authorities are striving to improve the efficiency of their product registration and pharmacovigilance operations. Gains can be made through wider use of information technology, electronic submission, global standardization (such as the ICP harmonization) and better dialogue with companies, scientists, patients and legislators. But with the emergence of complex phenomena like biosimilars and cell- and gene-based therapies, will the authorities be able deliver on their promise of processing applications in a few months rather than years? Here, industry experts provided an up-to-date overview.
|
| Chairman | | | France | Pharmaceutical Unit - DGE | | Speakers | | | France | Roche | | | United States | Tufts Center for the Study of Drug Development | | | France | Protein Expert | | | United Kingdom | GlaxoSmithKline |
| 13:30 - --:00 | | Closing Cocktail
|
 | RED BIOTECH |
| 09:00 - 10:30 | | Present and Future of BioDefense : Innovation in the detection of Emerging Infectious Diseases
|
| Despite the persistence of a number of political issues, there is increasing awareness that biodefense projects can usefully interact with public health programs with a shared goal of detecting, tracking and combating novel, emerging or re-emerging human pathogens or their products. Better detection techniques, more responsive vaccination campaigns and improved treatment regimens are key issues. This session will review the state of the art in the detection of emerging infectious diseases and will take a look at what the future of biofense may hold.
|
| Chairman | | Luc Van Hijfte | Belgium | Johnson & Johnson Pharmaceutical Research & Development | | Speakers | | | Belgium | Johnson and Johnson, NV | | | United States | Acambis | | | France | Pharmaleads | | | United States | Novavax, Inc. |
| 10:30 - 11:00 | | Coffee Break
|
| 11:00 - 13:00 | | Therapeutic Innovations against Cancer
|
| | | |